ImmunoGen Message Board - Msg: 31769905

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gary Mohilner who wrote (5604)	8/30/2018 8:14:47 PM
From: Gary Mohilner	Read Replies (1) of 5665

As we approach September things appear to be picking up. IMGN has two presentations upcoming in the next couple weeks at Investors conferences, but more importantly technical conferences will be upcoming as well as new trials should apparently be started by our partners and more data should be revealed by them as well. By the end of this year we should have top line results for the Phase 3 with IMGN853, and that could be huge. While combined with other drugs this drug is even more effective, the data should be worthy of an approval sometime next year. I'm not in any way putting down SGEN, just suggesting that investors compare the two companies and see if you don't agree with me that our market caps should be much closer than they are. It's my hope that IMGN rises to SGEN's level, time will tell. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next